Printer Friendly

Salix Pharmaceuticals Announces Issuance of Xifaxan(R) Patent.

RALEIGH, N.C. -- Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the issuance of a patent, entitled "Polymorphous Forms of Rifaximin, Processes for Their Production and Use Thereof in the Medicinal Preparations", by the United States Patent and Trademark Office. This patent, assigned patent number US 7,045,620, is believed to extend the patent coverage of the current form of rifaximin, which we market in the United States under the tradename XIFAXAN(R), until May 22, 2024. Alfa Wassermann S.p.A., the patent owner, has licensed rights to rifaximin in the United States to Salix Pharmaceuticals. The patent is a composition of matter and process patent that covers several physical states of XIFAXAN.

"The issuance of this patent is an important component of our XIFAXAN Life Cycle Management program," stated Carolyn Logan, President and Chief Executive Officer. "We continue to move forward with increased confidence in our efforts to discover, develop and commercialize XIFAXAN to its fullest potential."

Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix's strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Company's 150-member gastroenterology specialty sales and marketing team.

Salix markets COLAZAL(R) Capsules 750 mg, XIFAXAN(R) (rifaximin) tablets 200 mg, VISICOL(R) Tablets, OSMOPREP(TM) Tablets, AZASAN(R), Anusol-HC(R)Cream 2.5%, Anusol-HC(R) 25 mg Suppository, Proctocort(R) Cream 1% and Proctocort(R) Suppositories. MOVIPREP(R) and granulated mesalamine are under development.

For full prescribing information on Salix products, please visit www.salix.com.

Salix trades on the Nasdaq National Market under the ticker symbol "SLXP". For more information please contact the Company at 919-862-1000 or visit our web site at www.salix.com. Information on our web site is not incorporated in our SEC filings.

Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include management of rapid growth, risks of regulatory review and clinical trials, market acceptance for approved products, intellectual property risks, and the need to acquire additional products. The reader is referred to the documents that the Company files from time to time with the Securities and Exchange Commission.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:May 18, 2006
Words:400
Previous Article:Tiffany Announces 25% Increase in Quarterly Dividend.
Next Article:PTC to be Featured on Alexander Haig's World Business Review Series, May 21, 2006 on CNBC (As Paid Programming).
Topics:


Related Articles
Salix Pharmaceuticals Announces Appointment of William P. Forbes, Pharm. D. as Vice President, Research and Development and Chief Development Officer.
Salix Pharmaceuticals to Acquire InKine Pharmaceutical; Strategic Combination Creates Leading Specialty Pharmaceutical Company Focused on...
Salix Pharmaceuticals Moves Forward with XIFAXAN Travelers' Diarrhea Prevention Study; First Step toward XIFAXAN Filing for Prophylactic Indication.
Salix Announces Termination of XIFAXAN(TM) Co-Promotion; Reaffirms 2005 Guidance.
Salix Pharmaceuticals Acquires Patent-Protected, Liquid Peg Bowel Cleanser from Norgine; FDA Review Response Due April 2006.
Salix Expands XIFAXAN(R) Intellectual Property; Secures License Agreement With Cedars-Sinai Medical Center.
MoviPrep(R) Granted FDA Marketing Approval; New Two-Liter Liquid Bowel Cleansing Prep for Colonoscopy.
Salix Pharmaceuticals Reports 2Q2006 Results.
Salix Pharmaceuticals Announces Issuance Of MOVIPREP(R) Patent.
Salix Pharmaceuticals Reports 1Q2007 Results.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters